Kairos Pharma Prices IPO Of 1.55M Shares At $4.00 Per Share
Portfolio Pulse from Benzinga Newsdesk
Kairos Pharma has priced its IPO at $4.00 per share, raising $6.2 million. The company will trade on the NYSE American under the symbol 'KAPA' starting September 16, 2024. The funds will support clinical trials for lung and prostate cancer, as well as preclinical candidates.
September 16, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kairos Pharma's IPO is set at $4.00 per share, raising $6.2 million. The company will begin trading on the NYSE American under the symbol 'KAPA' on September 16, 2024. The proceeds will fund clinical trials for lung and prostate cancer, and advance preclinical candidates.
The IPO pricing and the start of trading on a major exchange are significant events for Kairos Pharma. The raised funds are earmarked for important clinical trials, which could impact the company's future growth and valuation positively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100